Safety and Efficacy of CRISPR/Cas9 mRNA Instantaneous Gene Editing Therapy to Treat Refractory Viral Keratitis

NCT04560790 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

3

Enrollment

INDUSTRY

Sponsor class

Conditions

Viral Keratitis
Blindness Eye
Herpes Simplex Virus Infection
Cornea

Interventions

DRUG: BD111 Adult single group Dose

Sponsor

Shanghai BDgene Co., Ltd.

Collaborators

[object Object]